Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Your search for esrd returned 20 results
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action
Plasma D-dimer had comparable accuracy to CRP, ESR, fibrinogen for diagnosing periprosthetic joint infection in patients with revision hip or knee arthroplasty
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.